Comparison of transgenic and adenovirus hACE2 mouse models for SARS-CoV-2 infection

Abstract

Severe acute respiratory syndrome CoV-2 (SARS-CoV-2) is currently causing a worldwide pandemic with high morbidity and mortality. Development of animal models that recapitulate important aspects of coronavirus disease 2019 (COVID-19) is critical for the evaluation of vaccines and antivirals, and understanding disease pathogenesis. SARS-CoV-2 has been shown to use the same entry receptor as SARS-CoV-1, human angiotensin-converting enzyme 2 (hACE2) [1-3]. Due to amino acid differences between murine and hACE2, inbred mouse strains fail to support high titer viral replication of SARS-CoV-2 virus. Therefore, a number of transgenic and knock-in mouse models, as well as viral vector-mediated hACE2 delivery systems have been developed. Here we compared the K18-hACE2 transgenic model to adenovirus-mediated delivery of hACE2 to the mouse lung. We show that K18-hACE2 mice replicate virus to high titers in the nasal turbinates, lung and brain, with high lethality, and cytokine/chemokine production. In contrast, adenovirus-mediated delivery results in viral replication to lower titers limited to the nasal turbinates and lung, and no clinical signs of infection. The K18-hACE2 model provides a stringent model for testing vaccines and antivirals, whereas the adenovirus delivery system has the flexibility to be used across multiple genetic backgrounds and modified mouse strains.

Cited by papers we hold 9

• A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic · 2022
  No notice
• Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19 · 2021
  No notice
• Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model · 2021
  Not checked
• Animal Models for COVID-19: Hamsters, Mouse, Ferret, Mink, Tree Shrew, and Non-human Primates · 2021
  Not checked
• Rapid generation of mouse model for emerging infectious disease with the case of severe COVID-19. · 2021
  Not checked
• Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2 · 2021
  No notice
• Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A · 2021
  No notice
• Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic · 2021
  No notice
• Lethality of SARS-CoV-2 infection in K18 human angiotensin-converting enzyme 2 transgenic mice · 2020
  No notice

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.